The short answer
Mineral antacids that reduce acidity can increase amphetamine aspartate absorption or blood levels and may increase side effects. The effect depends on the antacid ingredients; the records do not establish a spacing interval that reliably prevents it. Discuss the exact product with the prescriber before use; the cited guidance advises avoiding relevant gastrointestinal alkalinizing antacids.
What this answer covers
Applies to oral amphetamine aspartate and antacids that meaningfully reduce acidity; other heartburn medicines and mineral preparations are not interchangeable. Evidence includes a mixed-salt product containing this ingredient, without transferring effects from its other components.
- Supplement or preparation
- Antacids
- Medication ingredient
- amphetamine aspartate
Evidence and practical considerations
Absorption & effectiveness
Exact-amphetamine sources identify antacids, and labeling supports increased exposure from gastrointestinal alkalinization; the conclusion is conditional because the category is chemically heterogeneous. Exact amphetamine-aspartate labeling or an explicit noncausal-aspartate active-moiety bridge supports the PIN applicability stated here. Exact amphetamine aspartate identity is retained; the component-containing product bridge is explicit and limited to an amphetamine-moiety mechanism with a noncausal aspartate counterion.
- Exact scope
- mineral-containing antacid products with amphetamine aspartate
- Medication form and route
- oral amphetamine aspartate
- Timing or duration
- Relevant when the specific product meaningfully alkalinizes the gastrointestinal tract or urine.
What remains uncertain
- Calcium carbonate, magnesium hydroxide, aluminum hydroxide, sodium bicarbonate, proton-pump inhibitors, and H2 blockers are not interchangeable.
- No universal magnitude was established for all mineral antacids.
- Only the alkalinizing mechanism is retained.
- Active-moiety evidence was bridged to RxCUI 221057 only where sulfate is noncausal; mixed salts, other salts, combinations, prodrugs, brands, and formulation-specific effects were not transferred.
- No standalone amphetamine-aspartate finished-product effect was assumed.
- The component-containing product bridge is allowed only because the adjudicated mechanism concerns amphetamine and the aspartate counterion is noncausal; other components and formulation effects are excluded.
Factors that may matter: antacid ingredient; dose; timing; formulation; urinary pH; renal function.
Read the supporting source summaries
Source 1: FDA prescribing information (amphetamine-aspartate-containing product)
dailymed.nlm.nih.gov · Source check Jul 24, 2026
Population: Patients receiving an oral mixed-amphetamine product containing amphetamine aspartate.
Antacids are explicitly listed.
The finished product also contains amphetamine sulfate and dextroamphetamine salts. Applicability to RxCUI 221057 is limited to the label's amphetamine-moiety mechanism; formulation-specific magnitude and other-component effects are not transferred.
Research assessment: · Open full citations ↗
Side effects & toxicity
Regulatory and exact-amphetamine sources support exposure increase from alkalinizing antacids; toxicity relevance is conditional on the actual product and patient. Exact amphetamine-aspartate labeling or an explicit noncausal-aspartate active-moiety bridge supports the PIN applicability stated here. Exact amphetamine aspartate identity is retained; the component-containing product bridge is explicit and limited to an amphetamine-moiety mechanism with a noncausal aspartate counterion.
- Exact scope
- mineral-containing antacid products with amphetamine aspartate
- Medication form and route
- oral amphetamine aspartate
- Timing or duration
- Relevant while a specific antacid produces clinically meaningful alkalinization.
What remains uncertain
- Antacids are chemically heterogeneous; only meaningful alkalinizing products are retained.
- No controlled exact-pair toxicity incidence was found.
- Intrinsic antacid adverse effects are not part of this endpoint.
- Active-moiety evidence was bridged to RxCUI 221057 only where sulfate is noncausal; mixed salts, other salts, combinations, prodrugs, brands, and formulation-specific effects were not transferred.
- No standalone amphetamine-aspartate finished-product effect was assumed.
- The component-containing product bridge is allowed only because the adjudicated mechanism concerns amphetamine and the aspartate counterion is noncausal; other components and formulation effects are excluded.
Factors that may matter: antacid ingredient and dose; formulation; renal function; cardiovascular disease; psychiatric vulnerability; higher stimulant dose.
Read the supporting source summaries
Source 1: FDA prescribing information (amphetamine-aspartate-containing product)
dailymed.nlm.nih.gov · Source check Jul 24, 2026
Population: Patients receiving an oral mixed-amphetamine product containing amphetamine aspartate.
Antacids are named, and gastrointestinal alkalinizing agents are described as increasing exposure.
The finished product also contains amphetamine sulfate and dextroamphetamine salts. Applicability to RxCUI 221057 is limited to the label's amphetamine-moiety mechanism; formulation-specific magnitude and other-component effects are not transferred.
Research assessment: · Open full citations ↗
Timing & monitoring
Direct exact-amphetamine disclosure guidance plus regulatory avoidance language support management, conditional on the antacid ingredient. Exact amphetamine-aspartate labeling or an explicit noncausal-aspartate active-moiety bridge supports the PIN applicability stated here. Exact amphetamine aspartate identity is retained; the component-containing product bridge is explicit and limited to an amphetamine-moiety mechanism with a noncausal aspartate counterion.
- Exact scope
- mineral-containing antacid products with amphetamine aspartate
- Medication form and route
- oral amphetamine aspartate
- Timing or duration
- During use of the specific alkalinizing antacid; no universal timing interval is established.
What remains uncertain
- Not every heartburn product is a mineral antacid or alkalinizing agent.
- No universal time separation was validated.
- Product ingredient must be known before applying the rule.
- Active-moiety evidence was bridged to RxCUI 221057 only where sulfate is noncausal; mixed salts, other salts, combinations, prodrugs, brands, and formulation-specific effects were not transferred.
- No standalone amphetamine-aspartate finished-product effect was assumed.
- The component-containing product bridge is allowed only because the adjudicated mechanism concerns amphetamine and the aspartate counterion is noncausal; other components and formulation effects are excluded.
Factors that may matter: antacid ingredient; dose; timing; formulation; renal function; cardiovascular vulnerability.
Read the supporting source summaries
Source 1: FDA prescribing information (amphetamine-aspartate-containing product)
dailymed.nlm.nih.gov · Source check Jul 24, 2026
Population: Patients receiving an oral mixed-amphetamine product containing amphetamine aspartate.
Antacids are explicitly named.
The finished product also contains amphetamine sulfate and dextroamphetamine salts. Applicability to RxCUI 221057 is limited to the label's amphetamine-moiety mechanism; formulation-specific magnitude and other-component effects are not transferred.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Research summary published |
Article revision: 26b825023ef48dfd
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.